ARDXArdelyx, Inc.

ARDX Stock Price, Valuation & Chart | Ardelyx, Inc.

Compare

$3.800+0.04 (+1.06%)

At close · 02 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology ARDX intrinsic value ARDX calculated fair value vs price

Overview Financials Dividends Ratios

ARDX Historical price chart

ARDX Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization938.71M

PE Ratio-17.76

EPS-0.21

Trading Volume3.89M

Today's High/Low3.83/3.73

Dividend Yield0.00

52 Week High/Low8.4/3.68

Shares Outstanding247.03M

ARDX Financial Statement

ARDX Analyst ratings

ARDX Analysis & performance metrics

ARDX Company profile

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States…

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in…

ARDX Management team

Name

Position

Michael G. RaabCEO

President, Chief Executive Officer & Director

Laura A. Williams M.D., M.P.H.

Chief Patient Officer

Elizabeth A. Grammer Esq.

Chief Legal & Administrative Officer and Secretary

Caitlin Lowie

Vice President of Corporate Communications & Investor Relations

Mike Kelliher

Executive Vice President of Corporate Development & Strategy

David P. Rosenbaum Ph.D.

Head of Drug Discovery and Early Development

Eric Duane Foster

Chief Commercial Officer

Justin A. Renz CPA, MBACFO

Chief Financial & Operations Officer

Name

Position

Michael G. RaabCEO

President, Chief Executive Officer & Director

Laura A. Williams M.D., M.P.H.

Chief Patient Officer

Elizabeth A. Grammer Esq.

Chief Legal & Administrative Officer and Secretary

Caitlin Lowie

Vice President of Corporate Communications & Investor Relations

Mike Kelliher

Executive Vice President of Corporate Development & Strategy

David P. Rosenbaum Ph.D.

Head of Drug Discovery and Early Development

Eric Duane Foster

Chief Commercial Officer

Justin A. Renz CPA, MBACFO

Chief Financial & Operations Officer

Management Team

Michael G. RaabCEO

President, Chief Executive Officer & Director

Laura A. Williams M.D., M.P.H.

Chief Patient Officer

Elizabeth A. Grammer Esq.

Chief Legal & Administrative Officer and Secretary

Caitlin Lowie

Vice President of Corporate Communications & Investor Relations

Mike Kelliher

Executive Vice President of Corporate Development & Strategy

David P. Rosenbaum Ph.D.

Head of Drug Discovery and Early Development

Eric Duane Foster

Chief Commercial Officer

Justin A. Renz CPA, MBACFO

Chief Financial & Operations Officer

Management

Michael G. RaabCEO

President, Chief Executive Officer & Director

Laura A. Williams M.D., M.P.H.

Chief Patient Officer

Elizabeth A. Grammer Esq.

Chief Legal & Administrative Officer and Secretary

Caitlin Lowie

Vice President of Corporate Communications & Investor Relations

Mike Kelliher

Executive Vice President of Corporate Development & Strategy

David P. Rosenbaum Ph.D.

Head of Drug Discovery and Early Development

Eric Duane Foster

Chief Commercial Officer

Justin A. Renz CPA, MBACFO

Chief Financial & Operations Officer

Total 8 executives

ARDX Frequently asked questions

What is Ardelyx, Inc. (ARDX) Stock Price?

Current stock price of Ardelyx, Inc. (ARDX) stock is $3.800. The stock price is +1.06% higher in the session. The intraday range can be seen from this page. Volume of Ardelyx, Inc. (ARDX) stock is 3.89M.

Last updated at 02 Sept 2026, 08:00 pm.

Why is the Ardelyx, Inc. (ARDX) stock price going up or down today?

The stock price of Ardelyx, Inc. (ARDX) can change with earnings, company news, and overall market sentiment. Ardelyx, Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Ardelyx, Inc. stock expensive at its current price?

Whether Ardelyx, Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for ARDX on this page is -17.76. EPS on this page is -0.21. Compare those figures with peers and growth expectations before deciding if the current Ardelyx, Inc. price is justified.

How has the stock price of Ardelyx, Inc. (ARDX) performed historically?

Historical performance for Ardelyx, Inc. (ARDX) is shown on the price chart on this page. Review multi-period moves alongside volume to see how ARDX reacted to past earnings and market events.

Should I buy Ardelyx, Inc. (ARDX) stock, at this price?

Buying Ardelyx, Inc. (ARDX) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.